Circadian Angiopoietin-Like-4 as a Novel Therapy in Cardiovascular Disease

Trends Mol Med. 2021 Jul;27(7):627-629. doi: 10.1016/j.molmed.2021.04.007. Epub 2021 May 10.

Abstract

Angiopoietin-like 4 (ANGPTL4) is critical for regulating plasma lipids, and thus an attractive therapeutic target for cardiovascular diseases. Unfortunately, targeting ANGPTL4 results in a proinflammatory and ultimately lethal phenotype in animals. The serendipitous discovery of cardiac ANGPTL4 as a circadian protein reveals novel mechanistic insight and a solution for this therapeutic dilemma.

Keywords: ANGPTL4; chronotherapy; circadian; heart; ischemia; light.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiopoietin-Like Protein 4 / genetics
  • Angiopoietin-Like Protein 4 / metabolism*
  • Animals
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / genetics
  • Cardiovascular Diseases / metabolism
  • Gene Expression Regulation*
  • Humans
  • Molecular Targeted Therapy*

Substances

  • Angiopoietin-Like Protein 4